Not finding it? Sign in to also search OpenAlex live.
-
Serotonin transporter promoter methylation as a biomarker for depression chronicity2024 Neuroscience Applied article Neuroscience Neurotransmitter Receptor Influence on Behavior Open access
S.E.P. Bruzzone, Brenda W.J.H. Penninx, Edwin J. C. G. van den Oord, Nic J.A. van der Wee, Vibe G. Frøkjær, R. Jansen
0citations -
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT2022 American Journal of Hematology article Medicine Chronic Myeloid Leukemia Treatments Open access
Yves Chalandon, Giulia Sbianchi, Luuk A. Gras, Linda Köster, Jane Apperley, Jenny Byrne, +19 more
23citations -
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Johannes Schetelig, Patrice Chevallier, Michel van Gelder, Jennifer Hoek, Olivier Hermine, Ronjon K. Chakraverty, +22 more
8citations -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
5citations -
EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions2024 Journal of the European Academy of Dermatology and Venereology article Medicine Dermatology and Skin Diseases Open access
Sonja Ständer, Maniçoba Pereira, Claudia Zeidler, Franz Josef Legat, L. Misery, Louise Lönndahl, +24 more
18citations -
Diagnosis, treatment and monitoring of chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO) – Evidence, practice and consensus-based recommendations from the German pediatric rheumatology society (GKJR)
Anja Schnabel, Christiane Reiser, M. BEER, Normi Brück, C. Förster, V. Grote, +13 more
2citations -
Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
Andreas Hochhaus, F.-X. Mahon, Tim H. Brümmendorf, Phillipp D. Le Coutre, David Jacob Andorsky, Susanne Saußele, +14 more
3citations -
CML-277: Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study2020 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Chronic Myeloid Leukemia Treatments
Bruce Douglas Smith, Gianantonio Rosti, Tim H. Brümmendorf, Gail J. Roboz, Carlo B Gambacorti-Passerini, Aude Charbonnier, +6 more
2citations -
POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Stephen Anthony Strickland, David Jacob Andorsky, Tim H. Brümmendorf, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, +3 more
0citations -
CML-766: Primary Endpoint Results of the Phase 3b ASC4START Trial of Asciminib vs Nilotinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP): Time to Treatment Discontinuation Due to Adverse Events (TTDAE)2025 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Chronic Myeloid Leukemia Treatments
Stephen Anthony Strickland, Andreas Hochhaus, Susanne Saußele, François Xavier Mahon, Philipp le Coutre, Delphine Réa, +14 more
0citations -
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT
Alexandros Kanellopoulos, Linda Köster, Hugues de Lavallade, Guillermo Ortí, Sebastian Francis, Jakob Robert Passweg, +24 more
0citations -
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT2024 British Journal of Haematology article Medicine Hematopoietic Stem Cell Transplantation Open access
Francesco Onida, Luuk A. Gras, Junran Ge, Linda Köster, Rose‐Marie Hamladji, Jenny Byrne, +24 more
5citations -
Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo2026 JDDG Journal der Deutschen Dermatologischen Gesellschaft article Medicine Cutaneous lymphoproliferative disorders research Open access
Svenja Royeck, Henning Olbrich, Steffen Koschmieder, Claudia Zeidler, Felix Witte, Konstantin Agelopoulos, +5 more
1citations